Global Protein Therapeutics Market Outlook 2020
NEW YORK, Dec. 9, 2015 /PRNewswire/ -- Once a rarely used subset of medical treatments, protein therapies have now found application in a large number of medical conditions. Since the introduction of the first recombinant protein therapeutic, the human insulin, the protein therapeutics market has revolutionized tremendously. Due to its increased usage, the market holds huge potential for future growth and it is estimated that by the end of 2020, it may reach the mark of US$ 208 Billion. Furthermore, the launch of new products is also likely to propel the market growth.
According to our new research report, "Global Protein Therapeutics Market Outlook 2020", a large number of existing and new market players are rigorously involved in developing monoclonal antibodies (mAbs). The mAbs segment accounts for the largest share in the current protein therapeutic products. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments, which includes insulin, EPO, interferon, G-CSF, human growth hormone , blood clotting factors and FSH.
The report takes into account all the important aspects of the global protein therapeutics market, and projects the market during the period 2013-2020. Some of the key aspects included in the report are the market share analysis of key players and the segmental analysis. The report also provides in depth analysis of various applications of the above mentioned protein therapeutics. The current as well as the future market prospects of the applications of major protein therapeutics is also provided in the report.
Through in-depth and careful analysis of the worldwide developments, we have observed that the US continues to hold a dominant position in the global protein therapeutics market, as the country provides a major proportion of the products' sales. However, our team of researchers has come up with an analysis that the future landscape looks promising, with respect to major contribution from emerging economies, which can be attributed to increasing awareness among people and an increased healthcare expenditure owing to the increase in the disposable income.
The report also covers an advanced phase drug analysis. This chapter lists all the protein therapeutics of the major players, which are in the third phase of the clinical trial. This analysis will help the client in understanding the potential market for the future. It also helps understand the major segments, indications and players in Protein Therapeutics that will continue to rule the market.
The report also states market forces that would govern the market, the drivers for the market, the challenges encountered by the market players, and the opportunities that the new and existing market players could grab, thereby resulting in the growth of the market. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance.
The report provides insight about the lucrativeness of the industry through Porter's Five Forces Analysis. This analysis will help the industry players to understand the level of competition within an industry, and would assist in business strategy development.
At the end, the key players of the market have been enlisted. A brief business overview of every player has been provided along with its product portfolio. This is followed by the recent developments of the player that may impact the market in the future. Overall, the report will prove to be a complete source of knowledge, and analysis for clients and potential investors.
Read the full report: http://www.reportlinker.com/p01974624-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article